http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
BioTime Announces Update to Third Quarter 2018 Financial Results Conference Call
-
BioTime Receives Second Installment Payment of $10.8 Million From Juvenescence Ltd.
-
BioTime to Report Third Quarter 2018 Financial Results on November 8th, 2018
-
BioTime Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting
-
BioTime Announces November 16, 2018 Record Date and November 28, 2018 Distribution Date for the Distribution of Age-X Therapeutics Shares
-
BioTime to Present New OpRegen® Data at American Academy of Ophthalmology Annual Meeting on October 28th
-
BioTime to Present at the Upcoming Ladenburg Thalmann and MicroCap Conferences
-
BioTime to Participate on Industry Perspectives Roundtable at NEI Audacious Goals in Regenerative Medicine Workshop: Pathways for Retinal Cell Replacement Therapies
-
BioTime Warrants to Expire on October 1, 2018
-
BioTime Implements New Leadership Structure; Appoints Brian Culley as Chief Executive Officer
-
BioTime Implements New Leadership Structure; Appoints Brian Culley as Chief Executive Officer
-
BioTime Updates Timeline for Distribution of AgeX Shares to BioTime Shareholders
-
Asterias Biotherapeutics (AST) Reports Positive Outcome from 2nd Safety Review Committee Meeting & Open Enrollment for VAC2 Clinical Trial in Non-Small Cell Lung Cancer
-
Asterias Biotherapeutics Announces Positive Outcome from Second Safety Review Committee Meeting and Open Enrollment for VAC2 Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)
-
BioTime Closes $43.2 Million AgeX Share Sale Transaction With Juvenescence
-
BioTime’s CEO Adi Mohanty and CFO Russell Skibsted to Participate in Upcoming Panel and Conferences
-
AgeX Therapeutics Acquires Technology to Regulate Immune Tolerance
-
BioTime to Present Data at the Military Health System Research Symposium
-
BioTime Reports Second Quarter Results and Recent Corporate Accomplishments
-
BioTime to Receive $43 Million From Juvenescence
-
BioTime Announces the Start of an Investigator Initiated Study of Premvia™ Designed and Conducted by Dr. Gordon H. Sasaki
-
BioTime Announces Distribution Ratio for Distribution of AgeX Therapeutics Shares
-
Data from BioTime’s OpRegen® Program to Be Presented at AAO 2018
-
BioTime to Announce Second Quarter 2018 Results on August 2, 2018
-
Pre-Open Movers 07/12: (ZGNX) (GLMD) (CA) Higher; (ZN) (ACRX) (AVGO) Lower (more...)
-
Asterias Biotherapeutics (AST) Reports Positive Outcome from Safety Review Committee for AST-VAC2
-
AgeX Therapeutics CEO Dr. Michael D. West to Present at Ending Age-Related Diseases: Investment Prospects & Advances in Research, July 12 in New York City
-
Asterias Biotherapeutics Announces Positive Outcome from Safety Review Committee for AST-VAC2; Recommends Continuation of Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)
-
BioTime Announces July 31, 2018 Record Date for the Distribution of AgeX Therapeutics Shares
-
BioTime Awarded Grant From the NIH
-
BioTime Licenses GMP Cell Line to Goliver Therapeutics
-
Asterias Biotherapeutics Announces First Patient Dosed in First-in-Human Clinical Study of Immunotherapy AST-VAC2 in Non-Small Cell Lung Cancer
-
AgeX Therapeutics Closes on $5 Million Strategic Investment From Juvenescence
-
BioTime Announces Submission of Draft Registration Statement for a Proposed Distribution of Its AgeX Shares
-
AgeX Therapeutics Appoints John F. Mauldin to Board of Directors
-
BioTime to Present at the 8th Annual LD Micro Invitational
-
BioTime (BTX) Secures $1.9M Grant for Continued Development of OpRegen for Dry-AMD
-
BioTime Announces $1.9 Million Grant for Continued Development of OpRegen® for Dry-AMD
-
BioTime Further Expands OpRegen® Clinical Trial in Dry-AMD With the Opening of Two Additional U.S. Sites
-
AgeX Therapeutics CEO Dr. Michael D. West to Deliver Keynote Address at World Advanced Therapies & Regenerative Medicine Congress, May 18 in London
-
BioTime Reports First Quarter Results and Recent Corporate Accomplishments
-
AgeX Announces NIH Grant Award
-
BioTime Presents Updated OpRegen® Clinical Trial Data at ARVO
-
BioTime to Announce First Quarter 2018 Results on May 10, 2018
-
Data from BioTime’s OpRegen® and Retinal Restoration Programs to Be Presented at ARVO 2018
-
Data from BioTime’s OpRegen® Program to Be Presented at the Fifth Annual Retinal Cell and Gene Therapy Innovation Summit
-
BioTime (BTX) to Receive up to $3.5 million in Cash from Sale of Ascendance Biotechnology
-
BioTime Announces Cash Sale of Ascendance Biotechnology
-
BioTime Reports Fourth Quarter and Fiscal 2017 Results
-
BioTime Submits CE Mark Application for European Approval of Renevia®
